Ernexa Therapeutics Inc. (ERNA) Return on Invested Capital (2013 - 2026)

Ernexa Therapeutics' (ERNA) quarterly Return on Invested Capital came in at 0.84% in Q1 2026, up 7.11% on a QoQ basis from 0.91% in Q4 2025.

Ernexa Therapeutics Inc. (ERNA) Return on Invested Capital (2013 - 2026) Analysis & Trends

Ernexa Therapeutics (ERNA) has 13 years of Return on Invested Capital data on file, last reported at 0.84% in Q1 2026.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.84% (changed N/A YoY) and the FY2019 annual result came in at 0.09%, down 10.0% from the prior year.
Return on Invested Capital advanced to 0.84% in Q1 2026, from 0.91% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.06% in Q3 2023 to a low of 1.87% in Q2 2022.
A 4-year average of 0.74% and a median of 0.84% in 2026 frame the typical range for Return on Invested Capital.
Annual changes were most pronounced in 2022 — Return on Invested Capital tumbled 53 bps — and 2023, when it surged 181 bps.
Tracing ERNA's Return on Invested Capital over 4 years: stood at 1.87% in 2022, then soared by 96 bps to 0.08% in 2023, then plunged by 1026 bps to 0.91% in 2025, then advanced by 7 bps to 0.84% in 2026.
The last three Return on Invested Capital figures came in at 0.84% (Q1 2026), 0.91% (Q4 2025), and 1.61% (Q3 2025), per Business Quant data.

Download Data